Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Itacitinib

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Incyte axes JAK1 inhibitor from pipeline 2 years after PhIII flop crushed hopes
    Incyte axes JAK1 inhibitor from pipeline 2 years after PhIII flop crushed hopes

    04 Aug 2022

    // Kyle LaHucik ENDPTS

    https://endpts.com/incyte-axes-jak1-inhibitor-from-pipeline-2-years-after-a-phiii-flop-crushed-hopes/

    Kyle LaHucik ENDPTS
    04 Aug 2022
    Share Share
    Incyte sinks as itacitinib fails pivotal test in acute GVHD
    Incyte sinks as itacitinib fails pivotal test in acute GVHD

    04 Jan 2020

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/incyte-sinks-as-itacitinib-fails-pivotal-test-acute-gvhd

    Nick Paul Taylor FIERCE BIOTECH
    04 Jan 2020
    Share Share
    Incyte takes a beating as a key PhIII study flops in latest painful setback
    Incyte takes a beating as a key PhIII study flops in latest painful setback

    02 Jan 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200102005480/en

    BUSINESSWIRE
    02 Jan 2020
    Share Share
    Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib
    Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib

    22 Jan 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190122005260/en/Incyte-Announces-Patient-Treated-Phase-3-Clinical

    BUSINESSWIRE
    22 Jan 2019
    Share Share